CannabisNews420.com – Cannabis/Marijuana Industry News

Overall, the Australian cannabis market is still in its early stages of development and only legalized medicinal use of marijuana as recently as 2016. 

Similarly, the land down under also legalized medical marijuana exports in 2018, thanks to the passing of the Narcotic Drug Amendment (Cannabis) Regulations in February of that year. This means that medicinal marijuana products developed in Australia can now be exported to a “licensed recipient” in countries where the drug is legal.

While Australia may, finally, just be entering the cannabis industry, it is poised to have long-term potential. According to the GreenFund, the cannabis export market in Australia is projected to be worth AU$55 billion by 2025 thanks in part to its agriculture industry. In short, Australia’s role in the cannabis industry will certainly continue growing.


Find out what experts are saying about the future of cannabis

Read our new report today

Give me my free report!

In terms of legal recreational cannabis use in Australia, that decision still remains up in the air, although there is promise that it could happen sometime soon.

With that in mind, here the Investing News Network profiles 10 ASX cannabis stocks that are actively involved in developing products related to medical marijuana. The companies listed below have market capitalizations between AU$10 million and AU$500 million with data compiled from TradingView’s stock screener. The companies below are listed in order of market capitalization size from smallest to largest.

1. BOD Australia (ASX:BDA)

Market cap: AU$17 million

BOD Australia is largely focused on cannabis and hemp-related products. With its approach, the company is using a patented delivery for product development in therapeutic uses, over-the-counter (OTC) solutions, vertical integration and exporting to markets like Europe and Asia.

BOD Australia’s reach in Australia ranges from selling prescription and OTC products to more than 1,000 outlets, such as pharmacies, retail stores and healthcare chains in addition to holding distribution agreements with two pharmacy wholesalers in Australia.

2. Zelda Therapeutics (ASX:ZLD)

Market cap: AU$31.72 million

Zelda Therapeutics is focused on unmet clinical needs and using medicinal cannabis to treat a range of diseases and disorders. Its most common target areas include pain, anxiety and sleep.

The company is largely focused on developing treatment options from plant-based medicinal marijuana and is currently conducting two programs: a human clinical program with a focus on insomnia, autism and opioid reduction and a pre-clinical research program to test cannabinoids in breast, brain and pancreatic cancer. This program is also researching the role cannabinoids could play in treating diabetes-associated cognitive decline.


Keep up with major deals and investment opportunities in marijuana

 

Learn to profit from cannabis companies

 

Give me my free report!

3. MMJ Group Holdings (ASX:MMJ)

Market cap: AU$52.93 million

MMJ Group Holdings holds a wide range of cannabis investments, including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, research and development and retail.

Some of its investments include:

  • Harvest One Cannabis (TSXV:HVT), which develops health and wellness products;
  • Fire & Flower Holdings (TSXV:FAF), which is a recreational cannabis retailer that’s developed products such as cannabis oil, grinders, gear, pipes, rolling papers and accessories and topicals, to name a few;
  • MediPharm Labs (TSXV:LABS); a cannabis extraction company which received its cannabis oil production license from Health Canada in 2018. MediPharm Labs also launched cannabis extraction services in Australia and is waiting approval from the Office of Drug Control to produce cannabis oil.

4. Creso Pharma (ASX:CPH)

Market cap: AU$56.84 million

Creso Pharma was the first to important medical cannabis into Australia and wast he first to launch these products into Switzerland for people as well as animals. The company’s anibidoil product was the first hemp cannabidoil complementary feed in animal health thanks to a partnership with Virbac Switzerland.  Creso Pharma also launched cannaQIX in Switzerland, which was the first cannabidoil nutraceutical in human health.

The company’s medicinal cannabis products range in areas of therapeutics, nutraceuticals, animal health, lifestyle and topicals.

5. THC Global Group (ASX:THC)

Market cap: AU$59.29 million

THC Global Group prides itself as operating under a ‘farm to pharma’ pharmaceuticals approach and has secured a growing capacity thanks to two grow sites and a pharmaceuticals biomanufacturing facility.

The company has a variety of global partnerships and is focused on manufacturing and distributing hydroponics equipment, materials and nutrients.


Keep up with major deals and investment opportunities in marijuana

 

Learn to profit from cannabis companies

 

Give me my free report!

6. MGC Pharmaceuticals (ASX:MXC; OTCQB:MGCLF)

Market cap: AU$63.07 million

MGC Pharmaceuticals is a specialist medical cannabis company with a focus on phytocannabinoid-based medicine for the biopharmaceutical sector. The company aims to bring its cannabinoid-based pharmaceuticals to medical markets such as Europe, North America and Australasia, which includes Australia, New Zealand New Guinea and other islands in that region.

The company is targeting medical conditions such as epilepsy and Alzheimer’s disease and has three core products: the CannEpil, which is an oral oil treatment for seizures associated with drug resistant epilepsy; CogniCann, which is an oral spray using a specific THC:CBD ratio for dementia symptoms; and InCann, which are BiAcftive Capsules to treat Chron’s disease and Irritable Bowl Disease-related symptoms.

7. Botanix Pharmaceuticals (ASX:BOT)

Market cap: AU$76.51 million

While Botanix Pharmaceuticals is largely a pharma company, the company is currently working towards the first human trials using synthetic cannabidoil in a proprietary drug delivery system called Permetrex for direct skin delivery of the treatment.

Botanix Pharmaceuticals product pipeline includes four programs that are focused on treating acne, plaque psoriasis and atopic dermatitis. As such, because no human clinical studies have been done with using cannabidoil to treat skin diseases, the company is advancing three of its programs  with natural extract forms of cannabidoil.

8. Medlab Clinical (ASX:MDC)

Market cap: AU$82.30 million

Medlab Clinical is largely a medical research and development company focused on novel biotherapeutics such as nutraceuticals and pharmaceuticals, although it does have a cannabis element to medicines it is developing.

In terms of its medical cannabis approach, Medlab Clinical is developing pain management treatments and, in particular, assisted by medical cannabis as an alternative to opioid medication.


Find out what experts are saying about the future of cannabis

Read our new report today

Give me my free report!

9. Cann Group (ASX:CAN)

Market cap: AU$285.20 million

Cann Group was established in 2015 and was the first company in Australia awarded with a cannabis research license by the country’s Government Office of Drug Control in 2017. With this license, it provided Cann Group with the opportunity to cultivate cannabis for research.  The company was also issued Australia’s first medicinal marijuana cultivation license in 2017, which allows the company to produce Australia-grown medical cannabis.

10. AusCann Group Holdings (ASX:AC8)

Market cap: AU$330.23 million

AusCann Group Holdings is focused on developing, producing and selling its cannabis-based pharmaceuticals both locally and internationally.  The company is primarily targeting areas of medicine for neuropathic and chronic pain and intends to release a proprietary final dose in the form of a capsule.

With its medical approach, AusCann Group Holdings is also looking to target treatment resistant epilepsy, nausea caused by chemotherapy and spasticity and spasms in patients with multiple sclerosis.

Investor takeaway

These ASX-listed cannabis companies indicate that the cannabis industry in Australia is undoubtedly growing, meaning that investment opportunities in the industry will also be poised for additional growth. While recreational marijuana remains illegal down under, the medical cannabis industry is thriving, making that side of the sector worth considering.

As yet Australia has no timeline attached to the legality of recreational use of marijuana, but it will be a story to watch over the coming months for those interested in the space.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.


Keep up with major deals and investment opportunities in marijuana

 

Learn to profit from cannabis companies

 

Give me my free report!

The post 10 ASX Cannabis Stocks appeared first on Investing News Network.





Original Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here